TABLE 1.

Baseline characteristics.

Variable, N (%)	N = 46
Median follow‐up (months; median, IQR)	32 (24, 43)
Age (months; median, IQR)	55 (46, 59)
<40	7 (15%)
≥40	39 (85%)
HER2 status
2+	19 (41%)
3+	27 (59%)
ER status
<50	14 (30%)
≥50	32 (70%)
PR status
<50	36 (78%)
≥50	10 (22%)
Lines of treatment
First‐line	27 (59%)
Second‐line	19 (41%)
Visceral metastasis
No	26 (57%)
Yes	20 (43%)
Brain metastases
No	39 (87%)
Yes	6 (13%)
Bone metastases only
No	38 (82.6%)
Yes	8 (17.4%)
Radiotherapy
No	33 (72%)
Yes	13 (28%)
Adjuvant endocrine therapy
No	22 (48%)
Yes	24 (52%)
Adjuvant trastuzumab therapy
No	17 (37%)
Yes	29 (63%)
Trastuzumab (1 line)
No	23 (50%)
Yes	23 (50%)
Trastuzumab secondary resistance
No	21 (46%)
Yes	25 (54%)

Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IQR, interquartile range; PR, progesterone receptor.